Physician profile
David Eric Carleton
NPI 1508073644
$2,493.91
in general payments reported to CMS, 2019-2025
14 companies · $532 in 2025
The $532 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $347 · 2021: $282 · 2022: $465 · 2023: $369 · 2024: $320 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.42 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $490.85 | 2019-2025 | Evenity, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $243.71 | 2019-2023 | Tremfya |
| Pfizer INC. | $172.35 | 2020-2025 | |
| Horizon Therapeutics Plc | $99.66 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $99.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $92.39 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $70.92 | 2022-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $48.91 | 2021-2023 | |
| Genentech USA, INC. | $47.79 | 2019-2020 | |
| Boston Scientific Corporation | $43.50 | 2025 | Watchman Flx |
| Lilly USA, LLC | $42.43 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $39.00 | 2021-2025 | Simlandi |
| Ucb, INC. | $22.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.